Recent research and the current scenario as well as future market potential of “Personalized Medicine, Targeted Therapeutics And Companion Diagnostic Market To 2019 – Strategic Analysis Of Industry Trends, Technologies, Participants, And Environment” globally.
Cutting-edge new research by KellySciPub indicates that the core personalized medicine market will be worth over $149 billion by 2020 with a CAGR of 8.74%. This market is made up of companion diagnostics and targeted therapeutics and is dominated by oncology, cardiovascular and infectious disease targeted treatment and diagnostics. The report has already been procured by 21 of the top 25 Pharma companies globally. This newly published edition, is a revolutionary insight into the vertical growing market of personalized healthcare globally.
KellySciPub forecasts that the total personalised targeted therapeutic market, for all indications, will grow at a CAGR of 6.47% over the next five years. Strong vertical growth in the companion diagnostic segment however will see a CAGR of 23.71% to 2020, mainly coming from oncology, cardiovascular and infectious disease (HIV/HCV) tests. Advancing technologies within the liquid biopsy market is also driving the market and will see strategic growth over the next five years with a CAGR of 20.6%. The two segments of the liquid biopsy market are tumor cell enrichment products and tumor cell detection technologies.
Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics are more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine reduces the frequency of adverse drug reactions and therefore has a dramatic impact on health economics. Developmental and diagnostic companies benefit from lower discovery and commercialization costs and more specific market subtypes.
Get The Sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/368549
This new report gives a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 360 tables & figures over 393 pages. The personalized medicine market is presented as follows:
By Company (e.g., QIAGEN, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD)
By Segment (Targeted therapeutics, Companion Diagnostics)
By Sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology, pharmacogenomics, consumer genomics, molecular diagnostics, liquid biopsy)
By Therapy (Cancer, Cardiovascular, Infectious Disease)
Key Opinion Leaders that contributed to interview questions within the report include:
Iain D. Miller, PhD, MBA, Founder & CEO, Healthcare Strategies Group
Stephen Finn, MBBS, PhD, Associate Professor, Cancer Molecular Diagnostic Laboratory, Consultant Histopathologist and Head of Histopathology, St James’s Hospital and Trinity College Dublin, Ireland
Ronald Przygodzki, MD, Director, Genomic Medicine Implementation at U.S. Department of Veterans Affairs, Washington DC
Elaine Kenny, PhD, Founder, Elda Biotech, Dublin, Ireland
Chad Clark, Co-President and Chief Operating Officer, Precision for Medicine
Tobias Guennel, PhD, Principal, Biomarker and IVD Analytics, Precision for Medicine
David Parker, PhD, Vice President, Integrated Market Access, Precision for Medicine
Deborah Phippard, PhD, Vice President, Research, Precision for Medicine
Judi Smith, MS, Vice President, In Vitro Diagnostics Regulatory and Quality, Precision for Medicine
A wealth of financial data & business strategy information is provided including:
Company Financials, Sales & Revenue Figures
Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies
Business Model Strategies for Providers. Provider Systems and Academic Medical Centres
Business Model Strategies for Payers & Governments
Private and Public Funding and Personalized Medicine Reimbursement
Revisions to Current Payment Systems and Intellectual Property
How to Gain Market Penetration in the EU
Cost-effectiveness and Business Value of Personalized Medicine
Consumer genomics and POC market
Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations)
Comprehensive Account of Company Product Portfolios & Kits
SWOT, Economic & Regulatory Environment specifics include:
Key Strengths, Weaknesses and Threats Influencing Leading Player Position within the Market
Technologies Driving the Market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)
Top Fastest Growing Market Segments and Emerging Opportunities
Top Pharmaceutical Companies within the IPM by Market Share and Revenue
Comprehensive Product Portfolios, R&D Activity and Pipeline Therapeutics
M&A Activity and Future Strategies of Top Personalized Medicine Pharmacos
Personalized Medicine Regulation (UK, Germany, France, Spain, Italy)
CE-Marked Personalized Medicine/Diagnostic Tests
FDA Advances in Personalized Medicine Regulation
Browse More In Vitro Diagnostics Market Research Reports: http://www.marketresearchreports.biz/category/28
This report highlights a number of significant players and influential company’s and gives details of their operations, products, financials and business strategy.
Abbott Molecular Inc.
Admera Health (GENEWIZ)
Celera (Quest Diagnostics)
Danaher (Leica Biosystems)
deCode Genetics (Amgen)
Human Longevity Inc (Cypher Genomics)
Johnson & Johnson
Roche Molecular Diagnostics
Siemens Healthcare Diagnostics
Thermo Fisher Scientific
Updates on the personalized medicine, targeted therapeutic and companion diagnostic space have been included in this latest edition to include cutting edge material from international conferences, workshops and symposia.
Who should read this report?
Pharmaceutical, biotechnology and diagnostic companies with an interest in personalized medicine
Industry professionals and business strategists will discover key information to propel their policies
Investors will gain inside information to dominant players in the industry and future forecasts
Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment
This report will tell you if the companies mentioned are:
Strong, competitive players
Pooling their resources for specific growth and therapeutic areas
Investing strategically in R&D
Have a history of strategic M&A activity
This detailed report is supported with over 365 tables & figures over 393 pages and profiles the main pharmacos in personalized medicine.
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
To View The Latest Industry Press Releases: http://www.marketresearchreports.biz/pressreleases
90 Sate Street, Suite 700
Albany, NY 12207
Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz